Dados de dois grupos genéticos UFV1 e UFV2 de matrizes de codorna de corte, com 629 animais no primeiro arquivo e 707 no segundo, foram avaliados pela técnica de componentes principais. Foram consideradas as seguintes características para análise: peso da ave (P1, P2, P3 e P4), peso médio do ovo (POM1, POM2, POM3 e POM4), peso médio da casca (PCM1, PCM2, PCM3 e PCM4), peso médio da gema (PGM1, PGM2, PGM3 e PGM4), gravidade específica média do ovo (DM1, DM2, DM3 e DM4), largura média do ovo (LOM1, LOM2, LOM3 e LOM4), comprimento médio do ovo (COM1, COM2, COM3 e COM4), número de ovos (N1, N2, N3 e N4), idade ao primeiro ovo (IDPO) e taxa de postura total (TXT). Após a coleta dos dados, foi realizada uma análise de componentes principais, buscando, com isso, selecionar as características mais explicativas. Logo as características de maior importância na variância total tiveram seus parâmetros genéticos e correlações genéticas estimados. Para o grupo genético UFV1, foram: P1, PCM1, PCM3, PGM1, PGM2, PGM4, DM4, LOM2, LOM3, COM1 e IDPO, já para UFV2: P1, P2, PCM1, PCM4, DM3, LOM2 e LOM4. As altas estimativas de herdabilidade encontradas indicam uma grande variabilidade para as características de qualidade dos ovos. As correlações genéticas mostram a possibilidade de ganhos correlacionados entre peso corporal e as características de qualidade dos ovos. Pequena resposta à seleção para produção de ovos pode ser esperada para estes grupos genéticos.

PB (18, 20, 22, 24 and 26%) and three levels of EM (2700, 2900 and 3100kcal kg -1

RESUMO Objetivou-se no presente trabalho determinar herdabilidades de características de desempenho produtivo e reprodutivo de diferentes grupos genéticos de matrizes de codornas de corte, estimando os parâmetros genéticos por nascimento, 7, 14, 21, 28, 35, 42, 77, 112 birth, 7, 14, 21, 28, 35, 42, 77, 112

10, 70, 140, 210, 280, 350, 420, 770, 1120

Introduction: Bortezomib in combination with liposomal doxorubicin has shown convincing activity as induction therapy in frontline multiple myeloma (MM) patients with CR rates exceeding those seen with conventional induction therapy. The impact of this treatment on patient Quality-of-Life (QOL), determined by overall health status, cancer and neurotoxicity specific questionnaires, is of clinical interest. Methods: Newly diagnosed Autologous Stem Cell Transplant (ASCT) eligible MM patients were recruited from nine centres across Canada to this single-arm, open-label, Phase II study. Patients received three to four 21-day cycles of DBd induction therapy (bortezomib 1.3mg/m2 days 1, 4, 8, 11 + pegylated liposomal doxorubicin 30 mg/m2 day 4 + pulsed dexamethasone 40mg days 1–4, 8–11, 15–18 Cycle 1 and days 1–4 cycles 2–4), depending on rapidity of CR achieved, and were then followed post ASCT. Patients completed the European Quality of Life Questionnaire (EQ-5D), the European Organization for Research and Treatment of Cancer’s 30-item Quality of Life Questionnaire (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity questionnaire (FACT/GOG-Ntx) prior to each cycle and at study termination. Results: Fifty patients were enrolled to fulfill the sample size requirement. Mean age was 56.0 (±8.7) years, and 68% of patients were male. Sixty-five percent of the patients had Stage III disease and all but two patients had secretory disease. Mean baseline β2-microglobulin level was 4.2 (1.5–25.4) mg/mL. Overall best response post-induction was 98% (≥ Minimal Response), with a corresponding 26.8% combined complete response (CR) + near CR rate. There was no significant change in the total EQ-5D score throughout the study when compared to baseline. There was a significant improvement at end of study in the mean EQ-5D VAS self-rated health status (Δ+5.14, p<0.05) compared to baseline. Although not significant, there was a trend towards an increase in the proportion of patients reporting no problem in the mobility and anxiety/depression EQ-5D dimensions over the course of induction therapy. There were also no significant changes observed in the EORTC QLQ-C30 scores. Throughout the study, the FACT/GOG-Ntx scores showed no statistically significant changes over time from baseline, in agreement with the overall clinical safety profile observed. The largest mean score change from baseline was at the end-of-study time point (Δ+1.79, SD±6.07, p=0.06). Conclusion: Although this study was not powered to detect changes in QOL, preliminary results indicate that there is a trend towards improvement in QOL outcomes in multiple myeloma patients being treated with the DBd induction regimen. These results corroborate the safety and tolerability profile observed in the study.